OncoSec Medical (ONCS) and Its Competitors Head-To-Head Comparison
OncoSec Medical (NASDAQ: ONCS) is one of 198 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare OncoSec Medical to similar companies based on the strength of its institutional ownership, valuation, earnings, analyst recommendations, dividends, profitability and risk.
Institutional and Insider Ownership
9.0% of OncoSec Medical shares are held by institutional investors. Comparatively, 48.7% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 11.5% of OncoSec Medical shares are held by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a summary of recent ratings for OncoSec Medical and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|OncoSec Medical Competitors||480||2266||6197||119||2.66|
OncoSec Medical currently has a consensus price target of $5.33, suggesting a potential upside of 367.84%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.11%. Given OncoSec Medical’s stronger consensus rating and higher probable upside, equities analysts plainly believe OncoSec Medical is more favorable than its peers.
This table compares OncoSec Medical and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|OncoSec Medical Competitors||-4,053.35%||-118.54%||-44.06%|
Volatility & Risk
OncoSec Medical has a beta of 2.53, meaning that its stock price is 153% more volatile than the S&P 500. Comparatively, OncoSec Medical’s peers have a beta of 1.63, meaning that their average stock price is 63% more volatile than the S&P 500.
Earnings and Valuation
This table compares OncoSec Medical and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|OncoSec Medical||N/A||-$21.73 million||-0.97|
|OncoSec Medical Competitors||$207.79 million||-$2.30 million||0.59|
OncoSec Medical’s peers have higher revenue and earnings than OncoSec Medical. OncoSec Medical is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
About OncoSec Medical
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.
Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.